A Study to Evaluate the Efficacy and Safety of TEV-48125 (Fremanezumab) for the Prevention of Episodic Cluster Headache (ECH)

NCT02945046 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

169

Enrollment

INDUSTRY

Sponsor class

Stopped Study was terminated as a result of a pre-specified futility analysis at the interim of 150 participants completing the efficacy analysis of the study.

Conditions

Episodic Cluster Headache

Interventions

DRUG: Fremanezumab
DRUG: Placebo

Sponsor

Teva Branded Pharmaceutical Products R&D, Inc.